GIANNATEMPO, PATRIZIA
GIANNATEMPO, PATRIZIA
Universita' degli Studi di MILANO
Biomarker-driven immunotherapy for precision medicine in prostate cancer
2022 A. Ottini, P. Sepe, T. Beninato, M. Claps, V. Guadalupi, E. Verzoni, P. Giannatempo, G. Baciarello, F. De Braud, G. Procopio
Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006))
2020 G.L. Banna, N. Nicolai, G. Palmieri, M. Ottaviano, L. Balzarini, D. Barone, U. Basso, A. Bavila, F. Bertoni, F. Calliada, T. Cai, G. Carrafiello, C. Condello, L. Da Pozzo, D. Di Nardo, G. Fornarini, T.P. Galetti, A. Garolla, P. Giannatempo, L. Guerra, S. La Spina, L. Malatino, A. Marchiano', M. Monti, F.F. Morbiato, F. Morelli, F. Nole', S. Palazzi, G. Procopio, G. Rosti, C. Sacco, A. Salvetti, R. Salvioni, T. Sava, S. Secondino, S. Serpentini, C. Spreafico, I.M. Tavolini, F. Valcamonico, E. Verri, P. Zucali, U. De Giorgi
Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica
2019 G.L. Banna, N. Nicolai, G. Palmieri, M. Ottaviano, L. Balzarini, D. Barone, U. Basso, A. Bavila, F. Bertoni, F. Calliada, T. Cai, G. Carrafiello, C. Condello, L. Da Pozzo, D. Di Nardo, G. Fornarini, T. Prayer Galetti, A. Garolla, P. Giannatempo, L. Guerra, S. La Spina, L. Malatino, A. Marchiano', M. Monti, F.F. Morbiato, F. Morelli, F. Nole', S. Palazzi, G. Procopio, G. Rosti, C. Sacco, A. Salvetti, R. Salvioni, T. Sava, S. Secondino, S. Serpentini, C. Spreafico, I.M. Tavolini, F. Valcamonico, E. Verri, P. Zucali, U. De Giorgi
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma
2016 P. Pinciroli, H. Won, G. Iyer, S. Canevari, M. Colecchia, P. Giannatempo, D. Raggi, M.A. Pierotti, F.G. De Braud, D.B. Solit, J.E. Rosenberg, M.F. Berger, A. Necchi
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
2016 A. Necchi, S. Lo Vullo, L. Mariani, D. Raggi, P. Giannatempo, G. Calareso, E. Togliardi, F. Crippa, N. Di Genova, F. Perrone, M. Colecchia, B. Paolini, G. Pelosi, N. Nicolai, G. Procopio, R. Salvioni, F.G. De Braud
Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma.
2015 N. Nicolai, E. Bianchi, I. Donati, C. L’Acqua, C. Brunelli, D. Biasoni, M. Catanzaro, S. Stagni, L. Piva, T. Torelli, A. Necchi, D. Raggi, P. Giannatempo, E. Faré, M. Colecchia, M. Langer, C. Borreani, R. Salvioni
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma : a systematic review and meta-analysis of patient outcomes
2015 P. Giannatempo, T. Greco, L. Mariani, N. Nicolai, S. Tana, E. Farè, D. Raggi, L. Piva, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, B. Avuzzi, M. Maffezzini, G. Landoni, F. De Braud, A.M. Gianni, G. Sonpavde, R. Salvioni, A. Necchi
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
2015 E. Zanardi, E. Verzoni, P. Grassi, A. Necchi, P. Giannatempo, D. Raggi, F. De Braud, G. Procopio
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy
2015 A. Necchi, P. Giannatempo, B. Paolini, S. Lo Vullo, M. Marongiu, E. Farè, D. Raggi, N. Nicolai, L. Piva, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, M. Maffezzini, A.M. Gianni, F. De Braud, L. Mariani, G. Sonpavde, M. Colecchia, R. Salvioni
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation
2015 D. Raggi, L. Mariani, P. Giannatempo, S. Lo Vullo, D. Giardiello, N. Nicolai, L. Piva, D. Biasoni, M. Catanzaro, T. Torelli, S. Stagni, M. Maffezzini, G. Calareso, M. Magni, M. Di Nicola, E. Verzoni, P. Grassi, G. Procopio, F. De Braud, G. Pizzocaro, R. Salvioni, A. Necchi
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer
2014 A. Necchi, L. Mariani, P. Giannatempo, D. Raggi, E. Farè, N. Nicolai, L. Piva, D. Biasoni, M. Catanzaro, T. Torelli, S. Stagni, M. Maffezzini, G. Pizzocaro, F.G. De Braud, A.M. Gianni, R. Salvioni
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer : an open label, single-group, phase 2 trial
2014 A. Necchi, P. Giannatempo, L. Mariani, E. Farè, D. Raggi, M. Pennati, N. Zaffaroni, F. Crippa, A. Marchianò, N. Nicolai, M. Maffezzini, E. Togliardi, M.G. Daidone, A.M. Gianni, R. Salvioni, F. De Braud
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment
2013 P. Giannatempo, B. Paolini, R. Miceli, D. Raggi, N. Nicolai, E. Faré, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, L. Piva, L. Mariani, R. Salvioni, M. Colecchia, A.M. Gianni, A. Necchi
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes
2013 A. Necchi, N. Nicolai, L. Mariani, D. Raggi, E. Farè, P. Giannatempo, M. Catanzaro, D. Biasoni, T. Torelli, S. Stagni, A. Milani, L. Piva, G. Pizzocaro, A.M. Gianni, R. Salvioni
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
2012 A. Necchi, L. Mariani, N. Zaffaroni, L.H. Schwartz, P. Giannatempo, F. Crippa, C. Morosi, R. Lanocita, T. Sava, C. Ortega, C. Messina, C. Sacco, M. Pennati, M.G. Daidone, N. Nicolai, F. De Braud, A.M. Gianni, R. Salvioni